Literature DB >> 2873918

Cyclophosphamide treatment in polyarteritis nodosa.

P Oriente, A Riccio, C Farinaro, E Farinaro, R Scarpa, L Vignone, A Pucino.   

Abstract

Five male patients with polyarteritis nodosa were treated with cyclophosphamide as follows: 3 mg/Kg/die i.v. up to maximum of 3 g.; subsequently, 200 mg/die per os for two weeks, then 100 mg per os every other day for three months; finally, 100 mg every fourth day until the 18th month. One patient, who also had fever, received 25 mg/die of prednisone for the initial three weeks of treatment. Before treatment ESR, WBC, and circulating immune-complexes were increased, while C3a, C3c and C4 serum complement components levels were normal. Skin ulcers healed within 4 months. A progressive marked improvement of visceral damages in the first months of therapy have been noted (e.g. blood pressure values in normal range after suspension of concomitant antihypertensive treatment, regression of peripheral neuropathy, etc. etc.). No further ischemic lesions occurred during treatment. Significant decreases of ESR and serum immune-complexes levels were detected. No untoward effects due to cyclophosphamide were observed. These findings support the effectiveness of this drug in polyarteritis. The possibility of association with glucocorticoids during the acute phase of disease is also discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873918     DOI: 10.1007/bf02032357

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

Review 1.  THE ROLE OF ANTIGEN-ANTIBODY COMPLEXES IN DISEASE.

Authors:  F J DIXON
Journal:  Harvey Lect       Date:  1963

2.  Immunocytochemical observations in periarteritis nodosa.

Authors:  F PARONETTO; L STRAUSS
Journal:  Ann Intern Med       Date:  1962-02       Impact factor: 25.391

3.  The effect of cortisone on the lesions of periarteritis nodosa.

Authors:  A H BAGGENSTOSS; R M SHICK; H F POLLEY
Journal:  Am J Pathol       Date:  1951 Jul-Aug       Impact factor: 4.307

4.  A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis.

Authors:  A D Steinberg; J L Decker
Journal:  Arthritis Rheum       Date:  1974 Nov-Dec

5.  Cyclophosphamide in lupus nephritis: a controlled trial.

Authors:  A D Steinberg; H B Kaltreider; P J Staples; E J Goetzl; N Talal; J L Decker
Journal:  Ann Intern Med       Date:  1971-08       Impact factor: 25.391

6.  Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide.

Authors:  J L Turk; D Parker; L W Poulter
Journal:  Immunology       Date:  1972-10       Impact factor: 7.397

7.  Detection of antibodies to DNA by radioimmunoassay and immunofluorescence.

Authors:  L A Aarden; F Lakmaker; E R de Groot; A J Swaak; T E Feltkamp
Journal:  Scand J Rheumatol Suppl       Date:  1975

8.  Cyclophosphamide therapy of severe systemic necrotizing vasculitis.

Authors:  A S Fauci; P Katz; B F Haynes; S M Wolff
Journal:  N Engl J Med       Date:  1979-08-02       Impact factor: 91.245

9.  Controlled trial of cyclophosphamide in rheumatoid arthritis.

Authors:  A S Townes; J M Sowa; L E Shulman
Journal:  Arthritis Rheum       Date:  1976 May-Jun

10.  Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes.

Authors:  T Abel; B S Andrews; P H Cunningham; C M Brunner; J S Davis; D A Horwitz
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.